BSX Boston Scientific Corporation - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
BSX trades at a significant valuation premium to sector peers like DHR (P/E 45.42) and TMO (P/E 33.45), reflecting growth expectations, though the current P/E of 54.91 demands flawless execution.
- Forward P/E of 36.81 reflects growth premium and de-risked innovation cycle
- P/S of 8.04 justified by high-margin, recurring-revenue medical device model
- Current P/E of 54.91 is stretched vs sector average of 43.86
- Price/Book of 6.51 exceeds sector median, raising sustainability concerns
With 20.3% revenue growth and accelerating earnings momentum, BSX is positioned for continued outperformance, supported by positive price trends (up 5.1% last month) despite a 6M dip of -3.2%.
- 20.3% YoY revenue growth and 60% earnings growth signal strong demand tailwinds
- Pipeline in structural heart and neuromodulation offers multi-year expansion runway
- Forward P/E compression risk if growth slows post-2025
- Q/Q EPS growth flat at 0.0%, suggesting near-term inflection point
BSX has delivered a strong historical track record of earnings beats and profitability improvement, with 3Y and 5Y returns of +142.1% and +170.0%, respectively, underscoring long-term execution quality despite occasional misses.
- 10 of last 12 quarters beat EPS estimates, with average surprise of +6.68%
- 5-year share price return of +170% demonstrates durable investor confidence
- One significant earnings miss in Q1 2021 (EPS -26% vs est), indicating volatility risk
- ROE of 12.49% has been inconsistent vs sector leaders like AMGN (81.71%)
BSX maintains a healthier balance sheet than sector peers like AMGN (Debt/Equity 5.67), but the low quick ratio of 0.77 raises concerns about near-term liquidity, especially in a rising rate environment.
- Debt/Equity of 0.51 is conservative vs sector average of 1.15
- Operating margin expansion to 20.73% enhances cash flow resilience
- Quick ratio of 0.77 indicates limited liquid assets to cover short-term liabilities
- Missing cash flow data (OCF, FCF) limits visibility into operational liquidity
The absence of a dividend (0.00% yield, 0.0% payout ratio) contrasts with peers like PFE (dividend payer) and reduces total return potential, making BSX reliant on pure price appreciation.
- No dividend payout (0.00% yield), reducing appeal to income-oriented investors
- Lack of dividend history limits capital return visibility
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BSX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
Primary
|
+170.0% | +142.1% | +17.2% | -3.2% | +5.1% | +2.7% |
|
DHR
Danaher Corporation
Peer
|
+11.0% | -6.3% | -7.0% | +13.2% | +7.3% | +5.4% |
|
PFE
Pfizer Inc.
Peer
|
-9.7% | -38.6% | +3.3% | +13.6% | +4.6% | +2.6% |
|
SYK
Stryker Corporation
Peer
|
+61.8% | +68.1% | -4.6% | -7.7% | -2.0% | +1.7% |
|
AMGN
Amgen Inc.
Peer
|
+65.4% | +30.6% | +17.6% | +24.6% | +13.3% | +5.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corporation
|
BULLISH | $155.63B | 54.91 | 12.5% | 14.4% | $102.69 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $156.25B | 45.42 | 6.8% | 14.4% | $221.21 | |
|
PFE
Pfizer Inc.
|
NEUTRAL | $146.63B | 14.57 | 10.6% | 15.7% | $25.06 | |
|
SYK
Stryker Corporation
|
NEUTRAL | $142.8B | 47.6 | 14.0% | 12.1% | $362.22 | |
|
AMGN
Amgen Inc.
|
NEUTRAL | $181.33B | 26.02 | 81.7% | 19.5% | $336.74 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-06 | ZANE ELLEN M | Director | Sale | 12,891 | $1,266,978 |
| 2025-11-03 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $4,973,338 |
| 2025-11-03 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-10-30 | MAHONEY MICHAEL F | Chief Executive Officer | Gift | 149,992 | - |
| 2025-10-28 | ZANE ELLEN M | Director | Sale | 12,891 | $1,306,900 |
| 2025-10-01 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $4,923,327 |
| 2025-10-01 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-09-02 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $5,271,416 |
| 2025-09-02 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
| 2025-08-01 | FITZGERALD JOSEPH MICHAEL | Officer | Sale | 50,000 | $5,231,670 |
| 2025-08-01 | BUTCHER ARTHUR C | Officer | Sale | 17,313 | $1,811,520 |
| 2025-08-01 | LUDWIG EDWARD J. | Director | Gift | 500 | - |
| 2025-08-01 | BUTCHER ARTHUR C | Officer | Option Exercise | 17,313 | $429,493 |
| 2025-08-01 | MONSON JONATHAN R | Chief Financial Officer | Stock Award | 1,090 | - |
| 2025-08-01 | FITZGERALD JOSEPH MICHAEL | Officer | Option Exercise | 50,000 | $1,307,500 |
Wall Street Analysts
Professional analyst ratings and price targets